Loading…

Where Are We With the Management of Hypertension? From Science to Clinical Practice

The management of elevated blood pressure in patients at high cardiovascular risk is still a subject of debate. The authors review current international guidelines and results of large clinical trials and recent meta‐analyses to discuss the different approaches in patients at high risk for cardiovas...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical hypertension (Greenwich, Conn.) Conn.), 2009-02, Vol.11 (2), p.66-73
Main Authors: Farsang, Csaba, Naditch‐Brule, Lisa, Avogaro, Angelo, Östergren, Jan, Verdecchia, Paolo, Maggioni, Aldo, Van De Borne, Philippe, Lins, Robert, Roca‐Cusachs, Alexandre
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5096-745670e008bba96a26cee8acb8796d127aedc38da37c29cd66f463a98915db23
cites cdi_FETCH-LOGICAL-c5096-745670e008bba96a26cee8acb8796d127aedc38da37c29cd66f463a98915db23
container_end_page 73
container_issue 2
container_start_page 66
container_title The journal of clinical hypertension (Greenwich, Conn.)
container_volume 11
creator Farsang, Csaba
Naditch‐Brule, Lisa
Avogaro, Angelo
Östergren, Jan
Verdecchia, Paolo
Maggioni, Aldo
Van De Borne, Philippe
Lins, Robert
Roca‐Cusachs, Alexandre
description The management of elevated blood pressure in patients at high cardiovascular risk is still a subject of debate. The authors review current international guidelines and results of large clinical trials and recent meta‐analyses to discuss the different approaches in patients at high risk for cardiovascular events. The different treatment options are considered in view of the modern approach and of the different classes of drugs (diuretics, angiotensin‐converting enzyme inhibitors, calcium channel blockers, β‐blockers, and angiotensin II receptor blockers) currently in use. A case report is presented as an illustration of the difficulties related to the management of high blood pressure in patients at increased risk. The benefits of the use of 2 medications that include an inhibitor of the renin‐angiotensin‐aldosterone system and a calcium channel blocker or a diuretic are discussed. Choosing the proper drugs and correct doses are important considerations for the long‐term management of hypertension.
doi_str_mv 10.1111/j.1751-7176.2008.00066.x
format article
fullrecord <record><control><sourceid>wiley_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_559634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JCH066</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5096-745670e008bba96a26cee8acb8796d127aedc38da37c29cd66f463a98915db23</originalsourceid><addsrcrecordid>eNqNUe1KwzAUDaL4MX0FyQu05mNNGhBFhnOKorCBP0Oa3trMrh1pddvbm7kx9Z8hIZd7zzm5uQchTElMw7qYxlQmNJJUipgRksaEECHi5R463hX2Q5ywfiRC5gidtO2UkIRzRQ7REVWMMSHJMRq_luAB34TzGrbrStyVgJ9Mbd5gBnWHmwKPVnPwHdSta-prPPTNDI-tg9oC7ho8qFztrKnwize2cxZO0UFhqhbOtncPTYa3k8Eoeny-ux_cPEY2IUpEsp-EFiC0n2VGCcOEBUiNzVKpRE6ZNJBbnuaGS8uUzYUo-oIblSqa5BnjPRRtZNsFzD8yPfduZvxKN8bpbeo9RKCTRAneD_irDT5UZkE6fM6b6g_tb6V2pX5rPnUqJKeEBoF0I2B907Yeih2XEr32RU_1evx6PX699kV_-6KXgXr---0f4taIALjcABaugtW_hfXDYBQC_gXVvJ1V</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Where Are We With the Management of Hypertension? From Science to Clinical Practice</title><source>PubMed Central</source><creator>Farsang, Csaba ; Naditch‐Brule, Lisa ; Avogaro, Angelo ; Östergren, Jan ; Verdecchia, Paolo ; Maggioni, Aldo ; Van De Borne, Philippe ; Lins, Robert ; Roca‐Cusachs, Alexandre</creator><creatorcontrib>Farsang, Csaba ; Naditch‐Brule, Lisa ; Avogaro, Angelo ; Östergren, Jan ; Verdecchia, Paolo ; Maggioni, Aldo ; Van De Borne, Philippe ; Lins, Robert ; Roca‐Cusachs, Alexandre</creatorcontrib><description>The management of elevated blood pressure in patients at high cardiovascular risk is still a subject of debate. The authors review current international guidelines and results of large clinical trials and recent meta‐analyses to discuss the different approaches in patients at high risk for cardiovascular events. The different treatment options are considered in view of the modern approach and of the different classes of drugs (diuretics, angiotensin‐converting enzyme inhibitors, calcium channel blockers, β‐blockers, and angiotensin II receptor blockers) currently in use. A case report is presented as an illustration of the difficulties related to the management of high blood pressure in patients at increased risk. The benefits of the use of 2 medications that include an inhibitor of the renin‐angiotensin‐aldosterone system and a calcium channel blocker or a diuretic are discussed. Choosing the proper drugs and correct doses are important considerations for the long‐term management of hypertension.</description><identifier>ISSN: 1524-6175</identifier><identifier>EISSN: 1751-7176</identifier><identifier>DOI: 10.1111/j.1751-7176.2008.00066.x</identifier><identifier>PMID: 19222670</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adrenergic beta-Antagonists - therapeutic use ; Angiotensin II Type 1 Receptor Blockers - therapeutic use ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Calcium Channel Blockers - therapeutic use ; Comorbidity ; Diabetes Mellitus - diagnosis ; Diabetes Mellitus - epidemiology ; Diet, Fat-Restricted ; Diet, Sodium-Restricted ; Disease Progression ; Diuretics - therapeutic use ; Drug Therapy, Combination ; Female ; Humans ; Hypertension - diagnosis ; Hypertension - epidemiology ; Hypertension - therapy ; Metabolic Syndrome - diagnosis ; Metabolic Syndrome - epidemiology ; Middle Aged ; Practice Guidelines as Topic ; Randomized Controlled Trials as Topic ; Review Paper ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>The journal of clinical hypertension (Greenwich, Conn.), 2009-02, Vol.11 (2), p.66-73</ispartof><rights>2009 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5096-745670e008bba96a26cee8acb8796d127aedc38da37c29cd66f463a98915db23</citedby><cites>FETCH-LOGICAL-c5096-745670e008bba96a26cee8acb8796d127aedc38da37c29cd66f463a98915db23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673101/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673101/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19222670$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:118282930$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Farsang, Csaba</creatorcontrib><creatorcontrib>Naditch‐Brule, Lisa</creatorcontrib><creatorcontrib>Avogaro, Angelo</creatorcontrib><creatorcontrib>Östergren, Jan</creatorcontrib><creatorcontrib>Verdecchia, Paolo</creatorcontrib><creatorcontrib>Maggioni, Aldo</creatorcontrib><creatorcontrib>Van De Borne, Philippe</creatorcontrib><creatorcontrib>Lins, Robert</creatorcontrib><creatorcontrib>Roca‐Cusachs, Alexandre</creatorcontrib><title>Where Are We With the Management of Hypertension? From Science to Clinical Practice</title><title>The journal of clinical hypertension (Greenwich, Conn.)</title><addtitle>J Clin Hypertens (Greenwich)</addtitle><description>The management of elevated blood pressure in patients at high cardiovascular risk is still a subject of debate. The authors review current international guidelines and results of large clinical trials and recent meta‐analyses to discuss the different approaches in patients at high risk for cardiovascular events. The different treatment options are considered in view of the modern approach and of the different classes of drugs (diuretics, angiotensin‐converting enzyme inhibitors, calcium channel blockers, β‐blockers, and angiotensin II receptor blockers) currently in use. A case report is presented as an illustration of the difficulties related to the management of high blood pressure in patients at increased risk. The benefits of the use of 2 medications that include an inhibitor of the renin‐angiotensin‐aldosterone system and a calcium channel blocker or a diuretic are discussed. Choosing the proper drugs and correct doses are important considerations for the long‐term management of hypertension.</description><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Angiotensin II Type 1 Receptor Blockers - therapeutic use</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Comorbidity</subject><subject>Diabetes Mellitus - diagnosis</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>Diet, Fat-Restricted</subject><subject>Diet, Sodium-Restricted</subject><subject>Disease Progression</subject><subject>Diuretics - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Hypertension - diagnosis</subject><subject>Hypertension - epidemiology</subject><subject>Hypertension - therapy</subject><subject>Metabolic Syndrome - diagnosis</subject><subject>Metabolic Syndrome - epidemiology</subject><subject>Middle Aged</subject><subject>Practice Guidelines as Topic</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Review Paper</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>1524-6175</issn><issn>1751-7176</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqNUe1KwzAUDaL4MX0FyQu05mNNGhBFhnOKorCBP0Oa3trMrh1pddvbm7kx9Z8hIZd7zzm5uQchTElMw7qYxlQmNJJUipgRksaEECHi5R463hX2Q5ywfiRC5gidtO2UkIRzRQ7REVWMMSHJMRq_luAB34TzGrbrStyVgJ9Mbd5gBnWHmwKPVnPwHdSta-prPPTNDI-tg9oC7ho8qFztrKnwize2cxZO0UFhqhbOtncPTYa3k8Eoeny-ux_cPEY2IUpEsp-EFiC0n2VGCcOEBUiNzVKpRE6ZNJBbnuaGS8uUzYUo-oIblSqa5BnjPRRtZNsFzD8yPfduZvxKN8bpbeo9RKCTRAneD_irDT5UZkE6fM6b6g_tb6V2pX5rPnUqJKeEBoF0I2B907Yeih2XEr32RU_1evx6PX699kV_-6KXgXr---0f4taIALjcABaugtW_hfXDYBQC_gXVvJ1V</recordid><startdate>200902</startdate><enddate>200902</enddate><creator>Farsang, Csaba</creator><creator>Naditch‐Brule, Lisa</creator><creator>Avogaro, Angelo</creator><creator>Östergren, Jan</creator><creator>Verdecchia, Paolo</creator><creator>Maggioni, Aldo</creator><creator>Van De Borne, Philippe</creator><creator>Lins, Robert</creator><creator>Roca‐Cusachs, Alexandre</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>200902</creationdate><title>Where Are We With the Management of Hypertension? From Science to Clinical Practice</title><author>Farsang, Csaba ; Naditch‐Brule, Lisa ; Avogaro, Angelo ; Östergren, Jan ; Verdecchia, Paolo ; Maggioni, Aldo ; Van De Borne, Philippe ; Lins, Robert ; Roca‐Cusachs, Alexandre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5096-745670e008bba96a26cee8acb8796d127aedc38da37c29cd66f463a98915db23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Angiotensin II Type 1 Receptor Blockers - therapeutic use</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Comorbidity</topic><topic>Diabetes Mellitus - diagnosis</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>Diet, Fat-Restricted</topic><topic>Diet, Sodium-Restricted</topic><topic>Disease Progression</topic><topic>Diuretics - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Hypertension - diagnosis</topic><topic>Hypertension - epidemiology</topic><topic>Hypertension - therapy</topic><topic>Metabolic Syndrome - diagnosis</topic><topic>Metabolic Syndrome - epidemiology</topic><topic>Middle Aged</topic><topic>Practice Guidelines as Topic</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Review Paper</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Farsang, Csaba</creatorcontrib><creatorcontrib>Naditch‐Brule, Lisa</creatorcontrib><creatorcontrib>Avogaro, Angelo</creatorcontrib><creatorcontrib>Östergren, Jan</creatorcontrib><creatorcontrib>Verdecchia, Paolo</creatorcontrib><creatorcontrib>Maggioni, Aldo</creatorcontrib><creatorcontrib>Van De Borne, Philippe</creatorcontrib><creatorcontrib>Lins, Robert</creatorcontrib><creatorcontrib>Roca‐Cusachs, Alexandre</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>The journal of clinical hypertension (Greenwich, Conn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Farsang, Csaba</au><au>Naditch‐Brule, Lisa</au><au>Avogaro, Angelo</au><au>Östergren, Jan</au><au>Verdecchia, Paolo</au><au>Maggioni, Aldo</au><au>Van De Borne, Philippe</au><au>Lins, Robert</au><au>Roca‐Cusachs, Alexandre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Where Are We With the Management of Hypertension? From Science to Clinical Practice</atitle><jtitle>The journal of clinical hypertension (Greenwich, Conn.)</jtitle><addtitle>J Clin Hypertens (Greenwich)</addtitle><date>2009-02</date><risdate>2009</risdate><volume>11</volume><issue>2</issue><spage>66</spage><epage>73</epage><pages>66-73</pages><issn>1524-6175</issn><eissn>1751-7176</eissn><abstract>The management of elevated blood pressure in patients at high cardiovascular risk is still a subject of debate. The authors review current international guidelines and results of large clinical trials and recent meta‐analyses to discuss the different approaches in patients at high risk for cardiovascular events. The different treatment options are considered in view of the modern approach and of the different classes of drugs (diuretics, angiotensin‐converting enzyme inhibitors, calcium channel blockers, β‐blockers, and angiotensin II receptor blockers) currently in use. A case report is presented as an illustration of the difficulties related to the management of high blood pressure in patients at increased risk. The benefits of the use of 2 medications that include an inhibitor of the renin‐angiotensin‐aldosterone system and a calcium channel blocker or a diuretic are discussed. Choosing the proper drugs and correct doses are important considerations for the long‐term management of hypertension.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19222670</pmid><doi>10.1111/j.1751-7176.2008.00066.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1524-6175
ispartof The journal of clinical hypertension (Greenwich, Conn.), 2009-02, Vol.11 (2), p.66-73
issn 1524-6175
1751-7176
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_559634
source PubMed Central
subjects Adrenergic beta-Antagonists - therapeutic use
Angiotensin II Type 1 Receptor Blockers - therapeutic use
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Calcium Channel Blockers - therapeutic use
Comorbidity
Diabetes Mellitus - diagnosis
Diabetes Mellitus - epidemiology
Diet, Fat-Restricted
Diet, Sodium-Restricted
Disease Progression
Diuretics - therapeutic use
Drug Therapy, Combination
Female
Humans
Hypertension - diagnosis
Hypertension - epidemiology
Hypertension - therapy
Metabolic Syndrome - diagnosis
Metabolic Syndrome - epidemiology
Middle Aged
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Review Paper
Severity of Illness Index
Treatment Outcome
title Where Are We With the Management of Hypertension? From Science to Clinical Practice
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T16%3A16%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Where%20Are%20We%20With%20the%20Management%20of%20Hypertension?%20From%20Science%20to%20Clinical%20Practice&rft.jtitle=The%20journal%20of%20clinical%20hypertension%20(Greenwich,%20Conn.)&rft.au=Farsang,%20Csaba&rft.date=2009-02&rft.volume=11&rft.issue=2&rft.spage=66&rft.epage=73&rft.pages=66-73&rft.issn=1524-6175&rft.eissn=1751-7176&rft_id=info:doi/10.1111/j.1751-7176.2008.00066.x&rft_dat=%3Cwiley_swepu%3EJCH066%3C/wiley_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5096-745670e008bba96a26cee8acb8796d127aedc38da37c29cd66f463a98915db23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/19222670&rfr_iscdi=true